Dana-Farber/Harvard Cancer Center, CURE Program, Boston, MA.
Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA.
J Clin Oncol. 2024 Nov 10;42(32):3867-3879. doi: 10.1200/JCO.23.02311. Epub 2024 Sep 17.
Despite effective early-detection approaches and innovative treatments, Black women in the United States have higher breast cancer mortality rates compared with White women. The purpose of this systematic review and meta-analysis is to determine the extent of disparities in breast cancer survival between Black and White women according to tumor subtype.
A comprehensive database search was performed for full-text, English-language articles published from January 1, 2000, to December 31, 2022. Included studies compared survival between Black and White female patients with breast cancer within subtypes defined by hormone receptor and human epidermal growth factor receptor 2 (HER2)/neu (HER2; now known as ERBB2) status. Random-effects models were used to combine study-specific results and generate pooled relative risks (RRs) and 95% CIs for breast cancer-specific or overall survival (OS). A protocol for this review was registered in PROSPERO (CRD42021268212).
Eighteen studies including 228,885 (34,262 Black; 182,466 White) patients with breast cancer were identified. Compared with White women, Black women had a higher risk of breast cancer death for all tumor subtypes. The summary risk of breast cancer death was 50% higher among hormone receptor-positive HER2-negative [HER2-] tumors (RR, 1.50 [95% CI, 1.30 to 1.72]), 34% higher for hormone receptor+/HER2+ (RR, 1.34 [95% CI, 1.10 to 1.64]), 20% higher for hormone receptor-negative (-)/HER2+ (RR, 1.29 [95% CI, 1.00 to 1.43]), and 17% higher among individuals with hormone receptor-/HER2- tumors (hazard ratio, 1.17; 95% CI, 1.10 to 1.25). Black women also had poorer OS than White women for all subtypes.
These results suggest there are both subtype-specific and subtype-independent mechanisms that contribute to disparities in breast cancer survival between Black and White women, which require multilevel interventions to address and achieve health equity.
尽管美国采取了有效的早期检测方法和创新疗法,但黑人女性的乳腺癌死亡率仍高于白人女性。本系统评价和荟萃分析的目的是根据肿瘤亚型确定黑人女性和白人女性乳腺癌生存差异的程度。
对 2000 年 1 月 1 日至 2022 年 12 月 31 日发表的全文英文文章进行了全面的数据库搜索。纳入的研究比较了根据激素受体和人表皮生长因子受体 2(HER2;现称为 ERBB2)状态定义的亚型中,黑人与白人女性乳腺癌患者的生存情况。使用随机效应模型对研究特异性结果进行合并,并生成乳腺癌特异性或总生存(OS)的汇总相对风险(RR)和 95%置信区间(CI)。本综述的方案已在 PROSPERO(CRD42021268212)中注册。
共纳入 18 项研究,包括 228885 名(34262 名黑人;182466 名白人)乳腺癌患者。与白人女性相比,所有肿瘤亚型的黑人女性乳腺癌死亡风险更高。激素受体阳性 HER2 阴性(HER2-)肿瘤的乳腺癌死亡汇总风险高 50%(RR,1.50 [95%CI,1.30 至 1.72]),激素受体+/HER2+(RR,1.34 [95%CI,1.10 至 1.64])高 34%,激素受体阴性(-)/HER2+(RR,1.29 [95%CI,1.00 至 1.43])高 20%,激素受体/HER2-肿瘤高 17%(危险比,1.17;95%CI,1.10 至 1.25)。黑人女性在所有亚型中的 OS 也比白人女性差。
这些结果表明,在黑人女性和白人女性的乳腺癌生存差异中,存在既有亚型特异性又有亚型独立性的机制,需要采取多层次的干预措施来解决和实现健康公平。